Deal Details
Sanofi is carving out a package of 20 mature medicines along with three manufacturing facilities and passing them to Cheplapharm. The transition kicks off in 2027, with completion anticipated no later than Q3 of that same year. In exchange for the assets, Sanofi will hold a 26.4% equity position in Cheplapharm. The two companies have done similar transactions before, with Sanofi previously selling brands to the German group that specializes in tried‑and‑true, off‑patent drugs.
Why Sanofi is making this move
New CEO Belén Garijo is steering Sanofi toward more innovative products, cutting development on several medicines and tightening how future projects make it into the pipeline. The company is under pressure to set up meaningful deals to offset a looming revenue headwind from Dupixent, its top seller for skin and asthma conditions, which is set to begin shedding patent protections in the early 2030s. Sanofi has flagged late‑stage acquisitions in high‑growth areas as a possibility, with rare diseases singled out as a space of interest.
Steady investors focus on preserving gains while seeking reliable ways to grow wealth. Join Briefs Finance CEO Jaspreet Singh on September 29th for a FREE live investor workshop, How to Profit From A Dollar That's Losing its Value, where he shows how we're spotting investment opportunities as the dollar falls. Save your spot.
What It Means For Your Portfolio
If you hold big‑cap pharma or healthcare funds, this is one of those repositioning moves that can reshape a company's earnings mix. Swapping older cash‑flowing products for a stake in a specialist operator, while leaning into later‑stage dealmaking and potentially rare‑disease assets, signals Sanofi is bracing for Dupixent's patent clock. For everyday investors, watch how Sanofi's pipeline quality and deal activity evolve through 2027, and how the Cheplapharm stake contributes to stability as the company aims to shift more weight toward innovation.
A thoughtful plan helps protect your savings and pursue long term financial goals. Our CEO Jaspreet Singh is hosting a FREE live investor workshop, How to Profit From A Dollar That's Losing its Value, on September 29th. Sign up free to join him live.
